GLP-1 gains boost EBOS’ bottom line

The wholesaler and marketer indicated demand for high-value medicines has helped to offset headwinds from rising fuel costs Diversified company EBOS says network expansion and glucagon-like peptide-1 receptor agonists (GLP-1s) have helped its growth in the past 12 months, with community pharmacy, hospital medicines and medical technology among its key revenue drivers.   The wholesaler